{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:47:15Z","timestamp":1775123235750,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T00:00:00Z","timestamp":1374624000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s40265-013-0100-9","type":"journal-article","created":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T12:28:18Z","timestamp":1374668898000},"page":"1377-1383","source":"Crossref","is-referenced-by-count":33,"title":["Acotiamide: First Global Approval"],"prefix":"10.1007","volume":"73","author":[{"given":"Mary L.","family":"Nolan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley J.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,24]]},"reference":[{"issue":"3","key":"100_CR1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nrgastro.2013.14","volume":"10","author":"J Tack","year":"2013","unstructured":"Tack J, Talley NJ. Functional dyspepsia\u2014symptoms, definitions and validity of the Rome III criteria. Nat Rev Gastroenterol Hepatol. 2013;10(3):134\u201341.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"100_CR2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nrgastro.2013.11","volume":"10","author":"M Camilleri","year":"2013","unstructured":"Camilleri M, Stanghellini V. Current management strategies and emerging treatments for functional dyspepsia. Nat Rev Gastroenterol Hepatol. 2013;10(3):187\u201394.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"100_CR3","first-page":"96","volume":"25","author":"GP Karamanolis","year":"2012","unstructured":"Karamanolis GP, Tack J. Current management of functional dyspepsia: impact of Rome III subdivision. Ann Gastroenterol. 2012;25(2):96\u20139.","journal-title":"Ann Gastroenterol"},{"issue":"1","key":"100_CR4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2036.2012.05128.x","volume":"36","author":"BE Lacy","year":"2012","unstructured":"Lacy BE, Talley NJ, Locke GR 3rd, et al. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther. 2012;36(1):3\u201315.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"100_CR5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2982.2010.01486.x","volume":"22","author":"H Suzuki","year":"2010","unstructured":"Suzuki H, Hibi T. Acotiamide (Z-338) as a possible candidate for the treatment of functional dyspepsia. Neurogastroenterol Motil. 2010;22(6):595\u20139.","journal-title":"Neurogastroenterol Motil"},{"issue":"3","key":"100_CR6","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/jpet.110.174847","volume":"336","author":"Y Matsunaga","year":"2011","unstructured":"Matsunaga Y, Tanaka T, Yoshinaga K, et al. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride. J Pharmacol Exp Ther. 2011;336(3):791\u2013800.","journal-title":"J Pharmacol Exp Ther"},{"key":"100_CR7","unstructured":"Astellas P. Conclusion of co-development and co-marketing agreement on a functional dyspepsia agent Z-338\/YM443 in Japan with Zeria. 2008. http:\/\/www.astellas.com . Accessed 20 Jun 2013."},{"key":"100_CR8","unstructured":"Zeria Pharmaceutical Co. Ltd, Astellas Pharma Inc. Approval in Japan for treating functional dyspepsia with Acofide\u00ae. 2013. http:\/\/www.astellas.com . Accessed 20 Jun 2013."},{"key":"100_CR9","unstructured":"Zeria Pharmaceutical Co. Ltd, Astellas Pharma Inc. Launch of Acofide\u00ae in Japan for treating functional dyspepsia. 2013. http:\/\/www.astellas.com . Accessed 20 Jun 2013."},{"key":"100_CR10","unstructured":"Zeria Pharmaceutical Co. Ltd. Responding to cutting-edge medical demands. 2013. http:\/\/www.zeria.co.jp\/english\/comp\/co_0501.html . Accessed 24 Jun 2013."},{"key":"100_CR11","unstructured":"Zeria Pharmaceutical Co. Ltd, Astellas Pharma Inc. Acofide\u00ae tablets 100\u00a0mg: Japanese prescribing information. 2013. http:\/\/www.zeria.co.jp\/medi\/data\/acofide01\/pdf\/tenpu_201306.pdf . Accessed 18 Jun 2013."},{"key":"100_CR12","unstructured":"Matsueda K, Hongo M, Tack J, et al. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia\u2014100\u00a0mg t.i.d. is an optimal dosage. Neurogastroenterol Motil. 2010;22(6):618\u201325, e173."},{"key":"100_CR13","doi-asserted-by":"crossref","unstructured":"Tack JF, Stanghellini V, Holtmann G, et al. Efficacy and safety study of acotiamide (Z-338) in European patients with functional dyspepsia [abstract no. Tu1359]. Gastroenterology. 2011;140(5 Suppl.1):S805.","DOI":"10.1016\/S0016-5085(11)63337-4"},{"key":"100_CR14","unstructured":"Zeria Pharmaceutical Co. Ltd. To evaluate the efficacy and safety of acotiamide in subjects with functional dyspepsia [ClinicalTrials.gov identifier NCT00323817]. US National Institues of Health, ClinicalTrials.gov. 2011. http:\/\/www.clinicaltrials.gov . Accessed 14 Jun 2013."},{"key":"100_CR15","unstructured":"Astellas Pharma Inc. A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study of YM443 [Z 338, acotiamide] in subjects with functional dyspepsia [ClinicalTrials.gov identifier NCT00102310]. US National Institutes of Health, ClinicalTrials.gov. 2008. http:\/\/www.clinicaltrials.gov . Accessed 12 Jun 2013."},{"key":"100_CR16","doi-asserted-by":"crossref","unstructured":"Talley NJ, et al. A novel acetylcholine esterase inhibitor acotiamide hydrochloride (YM443) in functional dyspepsia: efficacy in a randomized, double-blind, placebo-controlled dose ranging trial [abstract no. 1053]. Gastroenterology. 2008;134(4 Suppl.1):A157\u20138.","DOI":"10.1016\/S0016-5085(08)60732-5"},{"issue":"6","key":"100_CR17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1136\/gutjnl-2011-301454","volume":"61","author":"K Matsueda","year":"2012","unstructured":"Matsueda K, Hongo M, Tack J, et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012;61(6):821\u20138.","journal-title":"Gut."},{"issue":"4","key":"100_CR18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000332404","volume":"84","author":"K Matsueda","year":"2011","unstructured":"Matsueda K, Hongo M, Ushijima S, et al. A long-term study of acotiamide in patients with functional dyspepsia: results from an open-label phase III trial in Japan on efficacy, safety and pattern of administration. Digestion. 2011;84(4):261\u20138.","journal-title":"Digestion"},{"key":"100_CR19","unstructured":"Zeria Pharmaceutical Co. Ltd, Yamanouchi Pharmaceutical Co. Ltd. Zeria and Yamanouchi sign letter of intent for development and marketing of the gastroprokinetic Z-338. 2002. http:\/\/www.yamanouchi.com . Accessed 20 Jun 2013."},{"key":"100_CR20","unstructured":"Zeria Pharmaceuticals Co. Ltd, Astellas Pharma Inc. Launch of Acofide\u00ae in Japan for treating functional dyspepsia. 2013. http:\/\/www.astellas.com\/en\/corporate\/news\/detail\/launch-of-acofide-in-japan-for.html . Accessed 5 Jul 2013."},{"issue":"11","key":"100_CR21","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1002\/jps.22649","volume":"100","author":"K Yoshii","year":"2011","unstructured":"Yoshii K, Hirayama M, Nakamura T, et al. Mechanism for distribution of acotiamide, a novel gastroprokinetic agent for the treatment of functional dyspepsia, in rat stomach. J Pharm Sci. 2011;100(11):4965\u201373.","journal-title":"J Pharm Sci"},{"key":"100_CR22","doi-asserted-by":"crossref","unstructured":"Doi Y, Murasaki O, Kaibara M, et al. Characterization of functional effects of Z-338, a novel gastroprokinetic agent, on the muscarinic M1, M2, and M3 receptors expressed in Xenopus oocytes. Eur J Pharmacol. 2004;505(1\u20133):31\u20135.","DOI":"10.1016\/j.ejphar.2004.10.003"},{"key":"100_CR23","unstructured":"Nagahama K, Matsunaga Y, Kawachi M, et al. Acotiamide, a new orally active acetylcholinesterase inhibitor, stimulates gastrointestinal motor activity in conscious dogs. Neurogastroenterol Motil. 2012;24(6):566\u201374, e256."},{"key":"100_CR24","doi-asserted-by":"crossref","unstructured":"Kanemoto Y, Ishibashi H, Doi A, et al. An electrophysiological study of muscarinic and nicotinic receptors of rat paratracheal ganglion neurons and their inhibition by Z-338. Br J Pharmacol. 2002;135(6):1403\u201314.","DOI":"10.1038\/sj.bjp.0704610"},{"issue":"2","key":"100_CR25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1540\/jsmr.36.69","volume":"36","author":"T Nakajima","year":"2000","unstructured":"Nakajima T, Nawata H, Ito Y. Z-338, a newly synthetized carboxyamide derivative, stimulates gastric motility through enhancing the excitatory neurotransmission. J Smooth Muscle Res. 2000;36(2):69\u201381.","journal-title":"J Smooth Muscle Res"},{"issue":"1\u20133","key":"100_CR26","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ejphar.2011.05.049","volume":"666","author":"M Kawachi","year":"2011","unstructured":"Kawachi M, Matsunaga Y, Tanaka T, et al. Acotiamide hydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats. Eur J Pharmacol. 2011;666(1\u20133):218\u201325.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"100_CR27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0022-3565(24)39036-6","volume":"294","author":"M Ogishima","year":"2000","unstructured":"Ogishima M, Kaibara M, Ueki S, et al. Z-338 facilitates acetylcholine release from enteric neurons due to blockade of muscarinic autoreceptors in guinea pig stomach. J Pharmacol Exp Ther. 2000;294(1):33\u20137.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"100_CR28","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1254\/jjp.89.356","volume":"89","author":"H Morita","year":"2002","unstructured":"Morita H, Abe K, Ito Y, et al. Possible involvement of M5 muscarinic receptor in the enhancing actions of the novel gastroprokinetic agent Z-338 on nifedipine-sensitive voltage-dependent Ca2+ currents in guinea pig stomach. Jpn J Pharmacol. 2002;89(4):356\u201365.","journal-title":"Jpn J Pharmacol"},{"issue":"1","key":"100_CR29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1540\/jsmr.46.31","volume":"46","author":"H Akaike","year":"2010","unstructured":"Akaike H, Jang II-S, Hori N, et al. Effects of Z-338, a novel gastroprokinetic agent, on the actions of excitatory and inhibitory neurotransmitters on neurons in area postrema. J Smooth Muscle Res. 2010;46(1):31\u201347.","journal-title":"J Smooth Muscle Res"},{"issue":"9","key":"100_CR30","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2982.2008.01135.x","volume":"20","author":"K Seto","year":"2008","unstructured":"Seto K, Sasaki T, Katsunuma K, et al. Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol Motil. 2008;20(9):1051\u20139.","journal-title":"Neurogastroenterol Motil"},{"issue":"3","key":"100_CR31","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1365-2982.2009.01261.x","volume":"21","author":"J Tack","year":"2009","unstructured":"Tack J, Masclee A, Heading R, et al. A dose-ranging, placebo-controlled, pilot trial of acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil. 2009;21(3):272\u201380.","journal-title":"Neurogastroenterol Motil"},{"key":"100_CR32","unstructured":"Kusunoki H, Haruma K, Manabe N, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil. 2012;24(6):540\u20135, e250\u20131."},{"key":"100_CR33","doi-asserted-by":"crossref","unstructured":"Adam B, Liebregis T, Zschau NB, et al. Z-338 improves meal-induced symptoms in functional dyspepsia; a double-blind, randomized, placebo controlled crossover study [abstract no. T1266]. Gastroenterol. 2009;136(5 Suppl.1):A535.","DOI":"10.1016\/S0016-5085(09)62461-6"},{"key":"100_CR34","unstructured":"Zeria Pharmaceutical Co. Ltd. The effects of Z-338 in subjects with and without functional dyspepsia [ClinicalTrials.gov identifier NCT00298194]. US National Institues of Health, ClinicalTrials.gov. 2009. http:\/\/www.clinicaltrials.gov . Accessed 25 Jun 2013."},{"key":"100_CR35","unstructured":"Astellas Pharma Inc. A phase I, randomized, double-blind, placebo- and active-controlled, crossover study to evaluate the effect of repeat oral doses of YM443 on cardiac repolarization in healthy male and female adult subjects [ClinicalTrials.gov identifier NCT00850746] US National Institutes of Health, ClinicalTrials.gov. 2010. http:\/\/www.clinicaltrials.gov . Accessed 18 Jun 2013."},{"key":"100_CR36","unstructured":"Oliver SD, Ward C, Ward J, et al. Z-338: phase I, single and multiple oral dose, safety, tolerability and pharmacokinetic studies in healthy male subjects [abstract no. 948 plus poster]. In: 7th world conference on clinical pharmacology and therapeutics (CPT) and the 4th congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), 16\u201320 July 2000, Florence."},{"issue":"2","key":"100_CR37","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejphar.2004.06.040","volume":"497","author":"S Furuta","year":"2004","unstructured":"Furuta S, Kamada E, Omata T, et al. Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338. Eur J Pharmacol. 2004;497(2):223\u201331.","journal-title":"Eur J Pharmacol"},{"key":"100_CR38","doi-asserted-by":"crossref","unstructured":"Matsueda K, Hongo M, Tack JF, et al. Efficacy of acotiamide (Z-338) in patients with postprandial distress syndrome or overlap of epigastric pain syndrome and postprandial distress syndrome in functional dyspepsia [abstract no. Tu1357]. Gastroenterology. 2011;140(5 Suppl. 1):S805.","DOI":"10.1016\/S0016-5085(11)63335-0"}],"updated-by":[{"DOI":"10.1007\/s40265-014-0236-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2014,6,4]],"date-time":"2014-06-04T00:00:00Z","timestamp":1401840000000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0100-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0100-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0100-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T13:23:17Z","timestamp":1746019397000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0100-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,24]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["100"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0100-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,24]]}}}